letrozole has been researched along with Diffuse Parenchymal Lung Disease in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lapatinib is an orally bioavailable dual inhibitor of the intracellular domain of both the HER2 protein and the epidermal growth factor receptor." | 1.43 | [A Case of Interstitial Pneumonitis Induced by Lapatinib plus Letrozole]. ( Yamamoto, C; Yamamoto, D; Yamamoto, M, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamamoto, D | 1 |
| Yamamoto, C | 1 |
| Yamamoto, M | 1 |
1 other study available for letrozole and Diffuse Parenchymal Lung Disease
| Article | Year |
|---|---|
[A Case of Interstitial Pneumonitis Induced by Lapatinib plus Letrozole].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; E | 2016 |